Almac Clinical Services Craigavon Facility Achieves Successful Inspection by MHRA

October 10, 2008

Almac Clinical Services is pleased to announce the completion of a successful mandatory inspection of its Craigavon (UK) operations by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The inspection was conducted from the 22nd to the 25th September 2008 and noted that the site was compliant with EU Good Manufacturing Practices, with no critical or major failures observed. This follows the recent successful voluntary inspection of Almac Clinical Services, Pennsylvania.

Commenting on the inspection, Paul O’Connor (Vice President, Quality) said: “We are extremely pleased that our UK operations have also undergone a positive and successful inspection by the MHRA. We have been providing clinical services from our European facility for twenty years and continue to see ourselves as a market leader in delivering quality services to our Pharmaceutical and Biotech clients alike.”

Paul added “I wish to thank all of the staff involved for their efforts in regards to this inspection. Both this outcome, along with the successful inspection of our Pennsylvanian facility, places Almac at the forefront of providing quality clinical supplies worldwide.”



Jonathan Calderwood

[email protected]

+44 28 38 363857

About Almac

The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, product development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors.

The company has almost 2,200 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $100m North American Headquarters started in July 08 and is expected to be completed 2010.

To find out more about Almac visit


Back to news